BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 31358770)

  • 1. ER-residential Nogo-B accelerates NAFLD-associated HCC mediated by metabolic reprogramming of oxLDL lipophagy.
    Tian Y; Yang B; Qiu W; Hao Y; Zhang Z; Yang B; Li N; Cheng S; Lin Z; Rui YC; Cheung OKW; Yang W; Wu WKK; Cheung YS; Lai PBS; Luo J; Sung JJY; Chen R; Wang HY; Cheng ASL; Yang P
    Nat Commun; 2019 Jul; 10(1):3391. PubMed ID: 31358770
    [TBL] [Abstract][Full Text] [Related]  

  • 2. O-GlcNAc transferase promotes fatty liver-associated liver cancer through inducing palmitic acid and activating endoplasmic reticulum stress.
    Xu W; Zhang X; Wu JL; Fu L; Liu K; Liu D; Chen GG; Lai PB; Wong N; Yu J
    J Hepatol; 2017 Aug; 67(2):310-320. PubMed ID: 28347804
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular Mechanisms: Connections between Nonalcoholic Fatty Liver Disease, Steatohepatitis and Hepatocellular Carcinoma.
    Kanda T; Goto T; Hirotsu Y; Masuzaki R; Moriyama M; Omata M
    Int J Mol Sci; 2020 Feb; 21(4):. PubMed ID: 32102237
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Knockout of the Nogo-B Gene Attenuates Tumor Growth and Metastasis in Hepatocellular Carcinoma.
    Zhu B; Chen S; Hu X; Jin X; Le Y; Cao L; Yuan Z; Lin Z; Jiang S; Sun L; Yu L
    Neoplasia; 2017 Jul; 19(7):583-593. PubMed ID: 28628795
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular profiling of nonalcoholic fatty liver disease-associated hepatocellular carcinoma using SB transposon mutagenesis.
    Kodama T; Yi J; Newberg JY; Tien JC; Wu H; Finegold MJ; Kodama M; Wei Z; Tamura T; Takehara T; Johnson RL; Jenkins NA; Copeland NG
    Proc Natl Acad Sci U S A; 2018 Oct; 115(44):E10417-E10426. PubMed ID: 30327349
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systemic loss of CD36 aggravates NAFLD-related HCC through MEK1/2-ERK1/2 signaling pathway.
    Zheng E; Chen Q; Xiao A; Luo X; Lu Q; Tian C; Liu H; Zhao J; Wei L; Yang P; Chen Y
    Biochem Biophys Res Commun; 2024 May; 707():149781. PubMed ID: 38492244
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Autophagy, NAFLD and NAFLD-Related HCC.
    Wu WKK; Zhang L; Chan MTV
    Adv Exp Med Biol; 2018; 1061():127-138. PubMed ID: 29956211
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nogo-B promotes tumor angiogenesis and provides a potential therapeutic target in hepatocellular carcinoma.
    Cai H; Saiyin H; Liu X; Han D; Ji G; Qin B; Zuo J; Shen S; Yu W; Wu J; Wu Y; Yu L
    Mol Oncol; 2018 Dec; 12(12):2042-2054. PubMed ID: 30019429
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bifidobacterium pseudolongum-generated acetate suppresses non-alcoholic fatty liver disease-associated hepatocellular carcinoma.
    Song Q; Zhang X; Liu W; Wei H; Liang W; Zhou Y; Ding Y; Ji F; Ho-Kwan Cheung A; Wong N; Yu J
    J Hepatol; 2023 Dec; 79(6):1352-1365. PubMed ID: 37459922
    [TBL] [Abstract][Full Text] [Related]  

  • 10. NAFLD Related-HCC: The Relationship with Metabolic Disorders.
    Zhang X
    Adv Exp Med Biol; 2018; 1061():55-62. PubMed ID: 29956206
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Non-alcoholic fatty liver disease associated with hepatocellular carcinoma: An increasing concern.
    Dhamija E; Paul SB; Kedia S
    Indian J Med Res; 2019 Jan; 149(1):9-17. PubMed ID: 31115369
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting of eIF6-driven translation induces a metabolic rewiring that reduces NAFLD and the consequent evolution to hepatocellular carcinoma.
    Scagliola A; Miluzio A; Ventura G; Oliveto S; Cordiglieri C; Manfrini N; Cirino D; Ricciardi S; Valenti L; Baselli G; D'Ambrosio R; Maggioni M; Brina D; Bresciani A; Biffo S
    Nat Commun; 2021 Aug; 12(1):4878. PubMed ID: 34385447
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nonalcoholic fatty liver disease and hepatocellular carcinoma.
    Zoller H; Tilg H
    Metabolism; 2016 Aug; 65(8):1151-60. PubMed ID: 26907206
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepatocellular carcinoma in the context of non-alcoholic steatohepatitis (NASH): recent advances in the pathogenic mechanisms.
    Lequoy M; Gigante E; Couty JP; Desbois-Mouthon C
    Horm Mol Biol Clin Investig; 2020 Feb; 41(1):. PubMed ID: 32112699
    [TBL] [Abstract][Full Text] [Related]  

  • 15. mTOR direct crosstalk with STAT5 promotes de novo lipid synthesis and induces hepatocellular carcinoma.
    Li T; Weng J; Zhang Y; Liang K; Fu G; Li Y; Bai X; Gao Y
    Cell Death Dis; 2019 Aug; 10(8):619. PubMed ID: 31409773
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Deranged hepatocyte intracellular Ca
    Ali ES; Rychkov GY; Barritt GJ
    Cell Calcium; 2019 Sep; 82():102057. PubMed ID: 31401389
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differences in metabolic and liver pathobiology induced by two dietary mouse models of nonalcoholic fatty liver disease.
    Zhang H; Léveillé M; Courty E; Gunes A; N Nguyen B; Estall JL
    Am J Physiol Endocrinol Metab; 2020 Nov; 319(5):E863-E876. PubMed ID: 32924526
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MicroRNA expression analysis in high fat diet-induced NAFLD-NASH-HCC progression: study on C57BL/6J mice.
    Tessitore A; Cicciarelli G; Del Vecchio F; Gaggiano A; Verzella D; Fischietti M; Mastroiaco V; Vetuschi A; Sferra R; Barnabei R; Capece D; Zazzeroni F; Alesse E
    BMC Cancer; 2016 Jan; 16():3. PubMed ID: 26728044
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Unique molecular characteristics of NAFLD-associated liver cancer accentuate β-catenin/TNFRSF19-mediated immune evasion.
    Wong AM; Ding X; Wong AM; Xu M; Zhang L; Leung HH; Chan AW; Song QX; Kwong J; Chan LK; Man M; He M; Chen J; Zhang Z; You W; Lau C; Yu A; Wei Y; Yuan Y; Lai PB; Zhao J; Man K; Yu J; Kahn M; Wong N
    J Hepatol; 2022 Aug; 77(2):410-423. PubMed ID: 35351523
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dietary cholesterol promotes steatohepatitis related hepatocellular carcinoma through dysregulated metabolism and calcium signaling.
    Liang JQ; Teoh N; Xu L; Pok S; Li X; Chu ESH; Chiu J; Dong L; Arfianti E; Haigh WG; Yeh MM; Ioannou GN; Sung JJY; Farrell G; Yu J
    Nat Commun; 2018 Oct; 9(1):4490. PubMed ID: 30367044
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.